# CareCloud, Inc.: Form 10-Q for the period ended Mar 31, 2020

- Company: [CareCloud, Inc.](/companies/ccld.md) (CIK 1582982)
- Form: 10-Q
- Filed: 2020-05-14
- Accepted by EDGAR: May 14, 2020, 16:31 ET
- Period: 2020-03-31
- Accession: 0001493152-20-008771
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1582982/000149315220008771/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1582982/000149315220008771/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-01-01 to 2020-03-31 | $21.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $2.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | −$2.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-01-01 to 2020-03-31 | $29.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | −$2.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | −$0.42 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | −$3.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2020-03-31 | $8.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $23.4m | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $89.8m | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $18.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $32.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-03-31 | $57.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 38,703 characters.

The following is a discussion of our condensed consolidated financial condition and results of operations for the three months ended March 31, 2020 and 2019, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Condensed Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “*Forward-Looking Statements”* on page 2 of this Quarterly Report on Form 10-Q.

### COVID-19 Pandemic

In December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced in Wuhan, China. Since then, SARS-CoV-2, and the resulting disease COVID-19, has spread to most countries, and all 50 states within the United States. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response, and under the Defense Production Act, the legislation that facilitates the production of goods and services necessary for national security and for other purposes. Numerous governmental jurisdictions, including the State of New Jersey where we maintain our principal executive offices, and those in which many of our U.S. and international offices are based, have imposed, and others in the future may impose, “shelter-in-place” orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Most states and the federal government, including the State of New Jersey, together with foreign jurisdictions in which we have operations centers, have declared a state of emergency related to the spread of COVID-19.

While the COVID-19 pandemic did not materially adversely affect the Company’s consolidated financial results and operations in the Company’s first quarter ended March 31, 2020, economic and health conditions in the United States and across most of the globe have changed rapidly since the end of the quarter. The Company has expanded its tele-health operations, which is an alternative to office visits. However, not all physicians are using telehealth and not to the same extent as previous office visits.

The COVID-19 pandemic is affecting the Company’s operations in the second quarter, and may continue to do so indefinitely thereafter. The pandemic may have an impact on the Company’s business, operations, and financial results and conditions, directly and indirectly, including, without limitation, impacts on the health of the Company’s management and employees, its operations, marketing and sales activities, and on the overall economy. The scope and nature of these impacts, most of which are beyond the Company’s control, continue to evolve and the outcomes are uncertain.

Due to the above circumstances and as described generally in this Quarterly Report on Form 10-Q, the Company’s consolidated results of operations for the three month period ended March 31, 2020 are not necessarily indicative of the results to be expected for the full fiscal year. Management cannot predict the full impact of the COVID-19 pandemic on the Company’s consolidated operations nor on economic conditions generally, including the effects on patient visits. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on future developments, and such effects could exist for an extended period of time even after the pandemic might end. See Item 1A. “Risk Factors” below for additional details.

### Overview

MTBC, Inc., together with its consolidated subsidiaries (“MTBC” or the “Company”), is a healthcare information technology company that provides a suite of proprietary web-based solutions and business services to healthcare providers. Our integrated Software-as-a-Service (“SaaS”) platform and business services are designed to help our clients increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. These solutions and services include:

Healthcare IT:

- Revenue cycle management (“RCM”) services;
- Proprietary, healthcare IT solutions, which are part of our RCM services, including:
- Electronic health records,
- Practice management software and related tools,
- Mobile Health (“mHealth”) solutions,
- Telehealth solutions,
- Healthcare claims clearinghouse, and
- Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients.
- Group purchasing services.

Practice Management Services:

- Comprehensive practice management services.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of approximately 450 experienced health industry experts throughout the United States, who are supported by our highly educated and specialized offshore workforce of approximately 2,500 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model has also allowed us to become a leading consolidator in our industry sector, in which we have gained a reputation for being able to acquire and transform distressed competitors into profitable operations of MTBC.

Adoption of our RCM solutions requires little or no upfront expenditure by a practice. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients because the vast majority of our revenues are based on a percentage of our clients’ collections. The standard fee for our complete, integrated, end-to-end solution is among the lowest in the industry. We currently provide services to more than 15,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 2,000 independent medical practices and hospitals.

During April 2019, the Company acquired substantially all of the revenue cycle management business of Etransmedia Technology, Inc. and its subsidiaries (together “Etransmedia”) through MTBC’s wholly owned subsidiary MTBC-Med, Inc. The Etransmedia acquisition added additional clients to the Company’s customer base and, similar to previous acquisitions, broadened the Company’s presence in the healthcare information technology industry through geographic expansion of its customer base and by increasing available customer relationship resources and specialized trained staff. The Company paid $1.6 million in cash for the acquisition.

On January 8, 2020, through a merger with a subsidiary, the Company acquired CareCloud Corporation (“CareCloud”), which has developed a highly acclaimed cloud-based platform including EHR, PM and patient experience capabilities. The Company paid $11.9 million in cash, assumed a working capital deficiency of approximately $5.1 million and issued 760,000 shares of the Company’s Series A Preferred Stock and two million warrants for the purchase of the Company’s common stock at prices ranging from $7.50 to $10.00 per share.

Our offshore operations in Pakistan and Sri Lanka accounted for approximately 11% and 18% of total expenses for the three months ended March 31, 2020 and 2019, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 80% for both the three months ended March 31, 2020 and 2019). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions as leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., Pakistan and Sri Lanka.

### Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

- Income tax expense (benefit) or the cash requirements to pay our taxes;
- Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Depreciation and amortization charges;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Impairment charges; and
- Changes in contingent consideration.

Set forth below is a presentation of our adjusted EBITDA for the three months ended March 31, 2020 and 2019:

*($ in thousands)*

|  | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Net revenue | $21,867 | $15,080 |
| GAAP net loss | (2,502) | (296) |
| Provision (benefit) for income taxes | 30 | (41) |
| Net interest expense | 80 | 17 |
| Foreign exchange (gain) loss / other expense | (424) | 244 |
| Stock-based compensation expense | 1,307 | 758 |
| Depreciation and amortization | 1,333 | 757 |
| Transaction and integration costs | 645 | 205 |
| Impairment charges | 298 | - |
| Change in contingent consideration | - | (64) |
| Adjusted EBITDA | **$767** | **$1,580** |

27

Adjusted operating income and adjusted operating margin exclude the following elements which are included in GAAP operating income (loss):

- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Impairment charges; and
- Changes in contingent consideration.

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three months ended March 31, 2020 and 2019:

*($ in thousands)*

|  | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Net revenue | $21,867 | $15,080 |
| GAAP net loss | (2,502) | (296) |
| Provision (benefit) for income taxes | 30 | (41) |
| Net interest expense | 80 | 17 |
| Other (income) expense - net | (445) | 82 |
| GAAP operating loss | (2,837) | (238) |
| GAAP operating margin | (13.0)% | (1.6)% |
| Stock-based compensation expense | 1,307 | 758 |
| Amortization of purchased intangible assets | 1,015 | 486 |
| Transaction and integration costs | 645 | 205 |
| Impairment charges | 298 | - |
| Change in contingent consideration | - | (64) |
| Non-GAAP adjusted operating income | **$428** | **$1,147** |
| Non-GAAP adjusted operating margin | 2.0% | 7.6% |

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Impairment charges;
- Changes in contingent consideration; and
- Income tax expense (benefit) resulting from the amortization of goodwill related to our acquisitions.

28

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net loss to non-GAAP adjusted net income for the three months ended March 31, 2020 and 2019:

*($ in thousands)*

|  | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| GAAP net loss | $(2,502) | $(296) |
| Foreign exchange (gain) loss / other expense | (424) | 244 |
| Stock-based compensation expense | 1,307 | 758 |
| Amortization of purchased intangible assets | 1,015 | 486 |
| Transaction and integration costs | 645 | 205 |
| Impairment charges | 298 | - |
| Change in contingent consideration | - | (64) |
| Income tax expense (benefit) related to goodwill | 15 | (56) |
| Non-GAAP adjusted net income | **$354** | **$1,277** |

Set forth below is a reconciliation of our GAAP net loss attributable to common shareholders, per share to our non-GAAP adjusted net income per share:

|  | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| GAAP net loss attributable to common shareholders, per share | $(0.42) | $(0.15) |
| Impact of preferred stock dividend | 0.22 | 0.13 |
| Net loss per end-of-period share | (0.20) | (0.02) |
| Foreign exchange (gain) loss / other expense | (0.03) | 0.02 |
| Stock-based compensation expense | 0.11 | 0.06 |
| Amortization of purchased intangible assets | 0.08 | 0.04 |
| Transaction and integration costs | 0.05 | 0.02 |
| Impairment charges | 0.02 | - |
| Change in contingent consideration | - | (0.01) |
| Income tax expense (benefit) related to goodwill | 0.00 | (0.00) |
| Non-GAAP adjusted net income per share | **$0.03** | **$0.11** |
| End-of-period shares | 12,367,293 | 12,009,742 |

For purposes of determining non-GAAP adjusted net income per share, the Company used the number of common shares outstanding at the end of March 31, 2020 and 2019. Non-GAAP adjusted net income per share does not take into account dividends paid on our preferred stock. No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per common share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

### Key Metrics

In addition to the line items in our condensed consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

***Providers and Practices Served:*** As of March 31, 2020, we provided services to an estimated universe of more than 15,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,000 independent medical practices and hospitals. In addition, we served approximately 160 clients who were not medical practices, but are service organizations who serve the healthcare community. As of March 31, 2019, we served approximately more than 11,000 providers representing approximately 1,800 practices. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

### Sources of Revenue

*Revenue:* We primarily derive our revenues from revenue cycle management services, reported in our Healthcare IT segment, which is typically billed as a percentage of payments collected by our customers. This fee includes RCM, as well as the ability to use our EHR and practice management software as part of the bundled fee. These bundled fees are classified as revenue cycle management revenue. These services accounted for approximately 60% and 70% of our revenues during the three months ended March 31, 2020 and 2019, respectively. Software-as-a-service fees, for clients not utilizing revenue cycle management services, accounted for approximately 17% of revenue during the three months ended March 31, 2020. Other Healthcare IT services, including printing and mailing operations and professional services, represented approximately 9% of revenues for both the three months ended March 31, 2020 and 2019.

We earned approximately 14% and 20% of our revenue from practice management services during the three months ended March 31, 2020 and 2019, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Practice Management segment.

### Operating Expenses

*Direct Operating Costs.* Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the condensed consolidated statements of operations.

*Selling and Marketing Expense.* Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

*Research and Development Expense.* Research and development expense consists primarily of personnel-related costs and third-party contractor costs.

*General and Administrative Expense.* General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees.

*Contingent Consideration.* Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

*Depreciation and Amortization Expense.* Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to ten years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our practice management clients is amortized on a straight-line basis over a period of twelve years.

*Impairment Charges.* Impairment charges represent charges recorded for a leased facility no longer being used by the Company. The Company is marketing the facility for sublease but has recorded an impairment for the remainder of the lease term.

*Interest and Other Income (Expense).* Interest expense consists primarily of interest costs related to our line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains (losses) and income earned from temporary cash investments.

*Income Tax.* In preparing our condensed consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of March 31, 2020 and December 31, 2019.

### Critical Accounting Policies and Estimates

The critical accounting policies and estimates used in the preparation of our condensed consolidated financial statements that we believe affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements presented in this Report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.

#### Leases:

We adopted ASU 2016-02: *Leases* (Topic 842) as of January 1, 2019. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability (current portion) and operating lease liability (noncurrent portion) in our condensed consolidated balance sheet at March 31, 2020. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

We use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease term includes options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the condensed consolidated balance sheet. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the leased and non-leased components as a single lease component. Some leases include escalation clauses and termination options that are factored into the determination of the future lease payments when appropriate.

There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 28, 2020.

### Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

|  | Three Months Ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Net revenue | 100.0% | 100.0% |
| Operating expenses: |  |  |
| Direct operating costs | 62.0% | 65.3% |
| Selling and marketing | 7.2% | 2.4% |
| General and administrative | 25.6% | 27.6% |
| Research and development | 10.7% | 1.7% |
| Change in contingent consideration | 0.0% | (0.4)% |
| Depreciation and amortization | 6.1% | 5.0% |
| Impairment charges | 1.4% | 0.0% |
| Total operating expenses | 113.0% | 101.6% |
| Operating loss | (13.0)% | (1.6)% |
| Interest expense - net | 0.4% | 0.1% |
| Other income (expense) - net | 2.0% | (0.5)% |
| Loss before income taxes | (11.4)% | (2.2)% |
| Income tax provision (benefit) | 0.1% | (0.3)% |
| Net loss | (11.5)% | (1.9)% |

### Comparison of the three months ended March 31, 2020 and 2019

|  | Three Months Ended March 31, 2020 | 2019 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $21,867,169 | $15,080,211 | $6,786,958 | 45% |

*Net Revenue.* Net revenue of $21.9 million for the three months ended March 31, 2020 increased by $6.8 million or 45% from revenue of $15.1 million for the three months ended March 31, 2019. Revenue for the three months ended March 31, 2020 includes approximately $1.2 million and $7.6 million respectively, from customers acquired in the Etransmedia and CareCloud acquisitions. Revenue for the three months ended March 31, 2020 includes $13.2 million relating to RCM services, $3.0 million for practice management services and $3.6 million related to SaaS services.

|  | Three Months Ended March 31, 2020 | 2019 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: |
| Direct operating costs | $13,566,730 | $9,847,540 | $3,719,190 | 38% |
| Selling and marketing | 1,581,353 | 361,399 | 1,219,954 | 338% |
| General and administrative | 5,592,725 | 4,162,076 | 1,430,649 | 34% |
| Research and development | 2,333,126 | 254,656 | 2,078,470 | 816% |
| Change in contingent consideration | - | (64,203) | 64,203 | (100)% |
| Depreciation | 274,381 | 207,617 | 66,764 | 32% |
| Amortization | 1,058,405 | 549,123 | 509,282 | 93% |
| Impairment charges | 297,651 | - | 297,651 | 100% |
| Total operating expenses | $24,704,371 | $15,318,208 | $9,386,163 | 61% |

*Direct Operating Costs.* Direct operating costs of $13.6 million for the three months ended March 31, 2020 increased by $3.7 million or 38% compared to direct operating costs of $9.8 million for the three months ended March 31, 2019, respectively. During the three months ended March 31, 2020, salary costs increased by $1.2 million, and outsourcing and processing costs increased by $1.9 million. Facilities costs increased by $83,000 for the three months ended March 31, 2020 and medical supplies for the managed practices increased by $336,000 for the three months ended March 31, 2020. The increase in the costs for the three months ended March 31, 2020 were primarily related to the Etransmedia and CareCloud acquisitions.

*Selling and Marketing Expense.* Selling and marketing expense of $1.6 million for the three ended March 31, 2020 increased by $1.2 million or 338% from selling and marketing expense of $361,000 for the three months ended March 31, 2019. The increase was primarily related to additional salary expense as a result of the CareCloud acquisition.

*General and Administrative Expense.* General and administrative expense of $5.6 million for the three months ended March 31, 2020 increased by $1.4 million or 34% compared to the same period in 2019. The increase in general and administrative expense was primarily related to additional salaries, facility costs and professional fees as a result of the Etransmedia and CareCloud acquisitions.

*Research and Development Expense.* Research and development expense of $2.3 million for the three months ended March 31, 2020 increased by $2.1 million from research and development expense of $255,000 for the three months ended March 31, 2019. During the three months ended March 31, 2020, the Company capitalized approximately $1.6 million of development costs in connection with its internal-use software.

*Contingent Consideration.* There was no change in contingent consideration for the three months ended March 31, 2020, compared to ($64,000) for three months ended March 31, 2019, which resulted from favorable settlements of the amount due to the owners of companies previously acquired during 2019.

*Depreciation.* Depreciation of $274,000 for the three months ended March 31, 2020 increased by $67,000 or 32% from depreciation of $208,000 for the three months ended March 31, 2019, primarily due to the property and equipment acquired as part of the Etransmedia and CareCloud acquisitions.

*Amortization Expense.* Amortization expense of $1.1 million for the three months ended March 31, 2020 increased by $509,000 or 93% from amortization expense of $549,000 for the three months ended March 31, 2019. The increase was primarily related to the intangible assets acquired from the Etransmedia and CareCloud acquisitions.

*Impairment Charges.* Impairment charges represent charges recorded for a leased facility no longer being used by the Company. The Company is marketing the facility for sublease.

|  | Three Months Ended March 31, 2020 | 2019 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: |
| Interest income | $37,757 | $78,200 | $(40,443) | (52)% |
| Interest expense | (117,545) | (95,396) | (22,149) | 23% |
| Other income (expense) - net | 445,143 | (81,030) | 526,173 | (649)% |
| Income tax provision (benefit) | 29,923 | (40,532) | 70,455 | (174)% |

*Interest Income.* Interest income of $38,000 for the three months ended March 31, 2020 decreased by $40,000 or 52% from interest income of $78,000 for the three months ended March 31, 2019. The interest income represents interest earned on temporary cash investments.

*Interest Expense.* Interest expense of $118,000 for the three months ended March 31, 2020, increased by $22,000 or 23% from interest expense of $95,000 for the three months ended March 31, 2019. The increase was primarily due to the utilization of line of credit. Interest expense includes the amortization of deferred financing costs, which was $48,000 each during the three months ended March 31, 2020 and 2019.

*Other (Expense) Income - net.* Other income - net was $445,000 for the three months ended March 31, 2020, compared to other expense - net of $81,000 for the three months ended March 31, 2019. Other income primarily represents foreign currency transaction gains and other expense primarily represents foreign currency transaction losses. These transaction gains and losses result from revaluing intercompany accounts whenever the exchange rate varies and are recorded in the condensed consolidated statements of operations.

*Income Tax Provision (Benefit).* The provision for income taxes was $30,000 for the three months ended March 31, 2020, compared to an income tax benefit of $41,000 for the three months ended March 31, 2019. As a result of the Company incurring a tax loss for 2020 and 2019, which has an indefinite life under the current tax rules, the federal deferred tax liability was offset against the federal net operating loss to the extent allowable in 2020 and 2019. The current income tax provision for the three months ended March 31, 2020 was approximately $15,000 and primarily relates to state minimum taxes and foreign income taxes. Although the Company is forecasting a return to profitability, it has incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at March 31, 2020 and 2019.

### Liquidity and Capital Resources

Borrowings under the SVB facility are based on 200% of repeatable revenue, reduced by an annualized attrition rate as defined in the agreement.

During the three months ended March 31, 2020, there was negative cash flow from operations of approximately $3.9 million, primarily because the Company assumed approximately $5.1 million of net payables as part of its acquisition of CareCloud. Even though a portion of the purchase price was retained by the Company to pay these expenses which relate to prior periods, these payments are treated as cash used in operations. As of March 31, 2020, the Company had approximately $8.4 million in cash, positive working capital of $5.2 million and $9.75 million drawn on its line of credit.

During April 2020, the Company sold 828,000 shares of its Series A Preferred Stock and received net proceeds of approximately $19.1 million, after issuance expenses. A portion of these proceeds was used to fully repay the line of credit.

During the quarter ended March 31, 2020, the Company paid $11.9 million in cash as part of the CareCloud purchase consideration.

The following table summarizes our cash flows for the periods presented:

|  | Three Months Ended March 31, 2020 | 2019 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: |
| Net cash (used in) provided by operating activities | $(3,883,414) | $937,509 | $(4,820,923) | (514)% |
| Net cash used in investing activities | (14,033,196) | (510,938) | (13,522,258) | 2647% |
| Net cash provided by (used in) financing activities | 6,809,586 | (2,586,271) | 9,395,857 | (363)% |
| Effect of exchange rate changes on cash | (491,789) | 213,864 | (705,653) | (330)% |
| Net decrease in cash | $(11,598,813) | $(1,945,836) | $(9,652,977) | 496% |

The loss before income taxes was $2.5 million for the three months ended March 31, 2020, which included $1.3 million and of non-cash depreciation and amortization. The loss before taxes for the three months ended March 31, 2019 was $336,000, which included $757,000 of non-cash depreciation and amortization.

### Operating Activities

Cash used in operating activities was $3.9 million and cash provided by operating activities was $938,000 during the three months ended March 31, 2020 and March 31, 2019, respectively. The increase in the net loss of $2.2 million for the three months ended March 31, 2020 as compared to the same period in 2019 included the following changes in non-cash items: an increase in depreciation and amortization expense of $730,000, an increase in stock based compensation expense of $550,000, a change in the provision (benefit) for deferred income taxes of $70,000 and an increase in interest expense of $47,000.

The net change in operating assets and liabilities was $3.9 million. Accounts payable, accrued compensation and accrued expenses decreased by $4.5 million for the three months ended March 31, 2020 compared to a decrease of $765,000 for the three months ended March 31, 2019 as the Company paid past due amounts from the CareCloud acquisition. Accounts receivable decreased by $302,000 for the three months ended March 31, 2020, compared with a decrease of $481,000 for the three months ended March 31, 2019. For the three months ended March 31, 2020 and 2019, the change in the lease liabilities is included in this amount.

### Investing Activities

Capital expenditures were $539,000 and $511,000 for the three months ended March 31, 2020 and 2019, respectively. The capital expenditures for the three months ended March 31, 2020 and 2019 primarily represented computer equipment purchased for the Pakistan office. Software development costs of $1.6 million for the three months ended March 31, 2020 were capitalized in connection with the development of software for providing revenue cycle management services and software-as-a-service offerings.

### Financing Activities

Cash provided by financing activities during the three months ended March 31, 2020 was $6.8 million and cash used in financing activities was $2.6 million for the three months ended March 31, 2019. Cash used in financing activities during the three months ended March 31, 2020 included $2.0 million of preferred stock dividends, $139,000 of repayments for debt obligations and $820,000 of tax withholding obligations paid in connection with stock awards issued to employees. Cash used in financing activities for three months ended March 31, 2019 included $1.5 million of preferred stock dividends, $85,000 of repayment for debt obligations and $872,000 of tax withholding obligations paid in connection with stock awards issued to employees. During the three months ended March 31, 2020, the Company drew the full amount available under its credit line of $9.75 million due to the uncertainty of the effect COVID-19 would have on its cash flows. There were no bank debt repayments during the three months ended March 31, 2020.

### Contractual Obligations and Commitments

We have contractual obligations under our line of credit. We also maintain operating leases for property and certain office equipment. We were in compliance with all SVB covenants as of March 31, 2020. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 28, 2020.

### Off-Balance Sheet Arrangements

As of March 31, 2020, and 2019, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

## Market risk

As filed, 175 characters.

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

## Controls and procedures

As filed, 2,212 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2020 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of March 31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

#### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 6,598 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q and the risk factor noted below, you should carefully consider the factors discussed in Part I—Item 1A. “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on February 28, 2020, which could materially affect our business, financial condition and/or future results and may be further impacted by the coronavirus pandemic. The risks described in our Annual Report on Form 10-K and herein are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and/or future results.

***Our business, financial condition, results of operations and growth could be harmed by the effects of the COVID-19 pandemic.***

We are subject to risks related to the public health crises such as the global pandemic associated with the coronavirus (“COVID-19”). In December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced in Wuhan, China. Since then, SARS-CoV-2, and the resulting disease COVID-19, has spread to most countries, and all 50 states within the United States. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response, and under the Defense Production Act, the legislation that facilitates the production of goods and services necessary for national security and for other purposes. Numerous governmental jurisdictions, including the State of New Jersey where we maintain our principal executive offices, and those in which many of our U.S. and international offices are based, have imposed, and others in the future may impose, “shelter-in-place” orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Most states and the federal government, including the State of New Jersey, together with foreign jurisdictions in which we have operations centers, have declared a state of emergency related to the spread of COVID-19. Such orders or restrictions, and the perception that such orders or restrictions could occur, have resulted in business closures, work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events, among other effects, thereby negatively impacting our customers, employees, and offices, among others. These challenges have been, and are anticipated to continue being, particularly difficult to manage in foreign jurisdictions in which we have offices due to, among other things, a reduced ability to enable efficient and secure work-from-home.

Health care organizations around the world, including our health care provider customers, have faced and will continue to face, substantial challenges in treating patients with COVID-19, such as the diversion of staff and resources from ordinary functions to the treatment of COVID-19, supply, resource and capital shortages and overburdening of staff and resource capacity. In the United States, governmental authorities have also recommended, and in certain cases required, that elective, specialty and other procedures and appointments, including certain primary care services, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will disproportionately harm the results of operations, liquidity and financial condition of these health care organizations and our health care provider customers. To the extent such health care provider customers experience challenges and difficulties, it will adversely affect our business operation and results of operations. We note, for example, that approximately 60% of our revenue is directly tied to the cash collected by our health care provider customers, which means that our short-term revenue has and is expected to decline as less patients visit their doctors during periods of social distancing. Further, a recession or prolonged economic contraction as a result of COVID-19 pandemic could also harm the business and results of operations of our enterprise customers, resulting in potential business closures, layoffs of employees and a significant increase in unemployment in the United States and elsewhere which may continue even after the pandemic. The occurrence of any such events may lead to reduced income for customers and reduced size of workforces, which could reduce our revenue and harm our business, financial condition and results of operations.

The widespread COVID-19 pandemic has resulted in, and may continue to result in, significant volatility and uncertainty in U.S and international financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock and Preferred Stock.

The global outbreak of COVID-19 continues to rapidly evolve. We have taken steps intended to mitigate the effects of the pandemic and to protect our global workforce including, but not limited to: moving a significant portion of our workforce to remote operations, enacting social distancing and hygiene guidelines set forth by the Centers for Disease Control and Prevention and World Health Organization at our offices, and discontinuing company travel and events, among others. Although we believe we have taken the appropriate actions, we cannot guarantee that these measures will mitigate all or any negative effects of the pandemic. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We cannot at this time precisely predict what effects the COVID-19 outbreak will have on our business, results of operations and financial condition, including due to uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the pandemic and the governmental responses to the pandemic. However, we will continue to monitor the COVID-19 situation closely.

Filed May 14, 2020.
Source: SEC EDGAR, the filing index for accession 0001493152-20-008771. Last ingested by Listed: Nov 5, 2026, 18:58 ET. No prices; not investment advice.
